MPM Medical Inc. :: Specializing in Pain Management & Advanced Wound Care

	MPM RadiaPlex^®Rx
	OraMagic^®Rx Oral Wound Rinse
	OraMagic^® Plus Oral Wound Rinse
	CoolMagic^TM Gel Sheets
	Regenecare^® Wound Gel
	Regenecare^®HA Wound Gel
	Regenecare^®HA Saturated Pads

MPM CoolMagic^TM Gel Sheets is excellent for reducing the pain from burns and skin reactions to radiation, cuts burns and abrasions.

"The Regenecare products are the first evidenced based wound and skin care products that provide local analgesia to control pain between dressing changes."

"With the addition of Hyaluronic Acid, Regenecare^®HA Gel provides greater moisture to the wound while reducing pain caused by debridement."

Home

About Us

Clinical Support

Scientific Publications, Presentations and Clinical Trials for MPM Topical Gel Products

RadiaPlexRx^TM Wound Care Gel

1. Patients Undergoing Radiation Treatment Were Clinically Evaluated for Skin Integrity, Pain and Itching in a Preliminary Trial Using RadiaPlexRxT Gel Containing 0.2% Hyaluronic Acid. Moore K, Haas ML, Lloyd K. Oncology Nursing Forum, 2005;32;2;479.

2. RadiaPlexRx^TM Gel Protects Cultured Skin Cells from Oxidative Free Radical Damage Induced by Hydrogen Peroxide and by Irradiation: A Pilot Study. R Gracy, Ph.D., K. Lloyd, M.S., J Phelps, Ph.D. Presented at Radiological Society of North America, 2004; 90th Scientific Assembly, SSA20-08;300.

3. A Pilot Study Evaluating Breast Cancer Patients Treated with a Topical Gel Containing 0.2% Hyaluronic acid for Efficacy Towards Radiation Dermatitis. M. Haas, Ph.D., ANP-C, Mountain Radiation Oncology, Ashville, NC, K. L. Lloyd, M.S. MPM Medical Inc., Irving TX

4. Randomized Trial: RadiaPlexRx Topical Gel vs. Control for Radiation Dermatitis in Breast Cancer Patients. T. Kuan Yu, M.D. Ph.D. M.D. Anderson Cancer Center, Houston Texas. Ongoing phase III trial of 93 patients, side by side evaluation for radiodermatitis severity and symptoms. Grant supported by University of Texas M.D. Anderson, and MPM Medical Inc., 2007.

Click here to read the supportive case trial listed at National Cancer Institute (www.cancer.gov)

Regenecare^® Wound Care Gel

5. A pilot crossover study to evaluate the use of Regenecare topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor (HER1/EGFR) inhibitors.
Citation: Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 19643
Author(s): S. Wong, K. E. Osann, K. P. Lloyd, C. M. Vasko, R. L. Arcinas, M. Mummaneni
Click here to read the supportive case trial listed at National Cancer Institute (www.cancer.gov)

6. A Pilot Cross-Over study to evaluate the use of Regenecare^® topical gel in patients with cutaneous toxicity caused by epidermal growth factor receptor (HER1/EGFR) inhibitors. SF Wong, Pharm D. K Lloyd MS, C Vasko RN, OCN, NP, M Mummaneni M.D., K Osann PhD. Presented at 9th National Conference on Cancer Nursing Research, 2007, 126, Oncology Nursing Forum, 2007, 34:1:216-217. Click here to read the supportive case trial listed at National Cancer Institute (www.cancer.gov)

7. Evaluation of Regenecare^® Topical Gel in the Treatment of Skin Rash Associated with Cetuximab (Erbitux^®), Tarceva^® and Other EGFR Inhibitors-Treated Cancer Patients. M. Kozloff, M.D., PA Gowland, RN, BSN, OCN, CCRC, J Vlamakis RN, OCN, J Koch RN BSN, G Ratko RN, BSN, L Gravitt RN, OCN, D Palmer CCRP, Ingalls Memorial Hospital, Cancer Research Center. Harvey Ill., 2007.

8. Evaluation of Cutaneous Skin Rash in Subjects Treated with Regenecare^® Topical Gel (Collagen, Aloe vera, & 2% Lidocaine) During Erbitux^® and Combination Therapies for Cancer. SF Wong, Pharm D, Western University of Health Sciences, College of Pharmacy, Pamona CA, Faculty in Residence Hematology Oncology Medical Group of Orange County, CA, Nov. 2006.

9. Case Studies Evaluating Regenecare^® Topical Gel, with 2% Lidocaine HCl, Collagen & Aloe Vera for Treating Cutaneous Rash Associated with EGFR (HER!/EGFR) Inhibitors. S F Wong, Pharm D, Western University of Health Sciences, College of Pharmacy, Pamona CA, Faculty in Residence Hematology Oncology Medical Group of Orange County, Orange CA, Nov. 2006.

10. Regenecare^® with Lidocaine Has Been Used Successfully on Over 400 Patients by Southwest Regional Wound Care Center, Lubbock, Texas to Anesthetize Wounds Prior to Debridement. Randall Wolcott M.D., P.A., American Professional Wound Care Association, 2006.

11. Evaluation of Topical Gel(With 2% Lidocaine-HCI) for Treatment of Adverse Rash Sympotoms Associated With EGFR/HER1 Inhibitors
M.F.Kozloff, P.A. Gowland, J.Vlamakis, J.Koch, K.P.Lloyd, J.B.Spalding
Ingalls Memorial Hospital, Cancer Research Center, Harvey, Illinois; MPM Medical Inc., Irving, Texas; University of North Texas, Denton, Texas Journal of Supportive Oncology 2007;5;8;405.

Address: 2301 Crown Ct, Irving TX 75038
Telephone: (972)893-4090 Fax: (972)893-4092